Compare NKSH & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | CDXS |
|---|---|---|
| Founded | 1891 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 256.3M |
| IPO Year | 1995 | 2008 |
| Metric | NKSH | CDXS |
|---|---|---|
| Price | $34.80 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.1K | ★ 878.5K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | 43.82 |
| EPS | ★ 0.78 | N/A |
| Revenue | $8,176,000.00 | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | $44.74 | ★ N/A |
| Revenue Growth | 9.39 | ★ 32.30 |
| 52 Week Low | $24.74 | $0.96 |
| 52 Week High | $40.00 | $3.87 |
| Indicator | NKSH | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 49.95 |
| Support Level | $34.32 | $2.39 |
| Resistance Level | $38.09 | $2.87 |
| Average True Range (ATR) | 0.78 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 71.19 | 42.34 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.